date,title,source
Oct-19-18,"Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-22-18,BRIEF-Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors,Reuters
Oct-22-18,BeiGene (BGNE): Moving Average Crossover Alert,Zacks
Oct-22-18,BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress,GlobeNewswire
Oct-24-18,BRIEF-Beigene Announces Acceptance Of Its New Drug Application In China,Reuters
Oct-24-18,BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,GlobeNewswire
Nov-01-18,BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting,GlobeNewswire
Nov-01-18,Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene,ACCESSWIRE
Nov-05-18,BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology,GlobeNewswire
Nov-07-18,BRIEF-Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib,Reuters
Nov-07-18,BeiGene Reports Third Quarter 2018 Financial Results,GlobeNewswire
Nov-07-18,BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,GlobeNewswire
Nov-08-18,Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors,PR Newswire
Nov-13-18,BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Nov-15-18,BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%,Zacks
Nov-15-18,Priority Review Granted to BeiGenes New Drug Applications for Zanubrutinib and Tislelizumab in China,GlobeNewswire
Nov-16-18,BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology,GlobeNewswire
Nov-20-18,BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference,GlobeNewswire
Nov-21-18,Analysts Take Action on Health Care Stocks,GuruFocus.com
Nov-27-18,"BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates",Reuters
Nov-27-18,"Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks Azymetric and EFECT Platforms Globally",Business Wire
Nov-28-18,"Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Nov-28-18,Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy?,Zacks
Nov-30-18,"Chinese biotech stocks hit by a double whammy, which means its time to buy",MarketWatch
Nov-30-18,Can The Uptrend Continue for BeiGene (BGNE)?,Zacks
Dec-03-18,BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkins Lymphoma at the 60th American Society of Hematology Annual Meeting,GlobeNewswire
Dec-10-18,BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress,GlobeNewswire
Dec-12-18,"Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds?",Insider Monkey
Dec-17-18,BRIEF-Beigene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab,Reuters
Dec-17-18,"BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer",GlobeNewswire
Dec-20-18,"Has BeiGene, Ltd. (NASDAQ:BGNE) Got Enough Cash?",Simply Wall St.
Dec-21-18,Our Top Stock Idea in Chinas Biotech Revolution,Motley Fool
Dec-24-18,Don't Miss Chinese Biotechs,Motley Fool
Jan-03-19,BRIEF-Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd,Reuters
Jan-03-19,Here's Why BeiGene Is Taking a Hit Today,Motley Fool
Jan-03-19,BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
Jan-11-19,Engaged Capital Helps Rethink Benchmark Electronics,Barrons.com
Jan-14-19,BRIEF-Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib,Reuters
Jan-14-19,BRIEF-Beigene Receives FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma,Reuters
Jan-14-19,BeiGene drug gets 'breakthrough therapy' designation from FDA,MarketWatch
Jan-14-19,BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma,GlobeNewswire
Jan-17-19,6 Stocks Beating the Market,GuruFocus.com
Feb-07-19,BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum  Oncology Day,GlobeNewswire
Feb-13-19,"BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong",GlobeNewswire
Feb-19-19,BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma,GlobeNewswire
Feb-19-19,"Market Trends Toward New Normal in CenturyLink, Textainer Group, BeiGene, Nova Measuring Instruments, One Liberty Properties, and Westwood Holdings Group  Emerging Consolidated Expectations, Analyst Ratings",GlobeNewswire
Feb-21-19,"Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares?",Simply Wall St.
Feb-22-19,BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference,GlobeNewswire
Feb-27-19,BRIEF-Beigene Reports Qtrly Loss Per Share Of $0.35,Reuters
Feb-27-19,BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results,GlobeNewswire
Feb-27-19,BeiGene Ltd. Sponsored ADR to Host Earnings Call,ACCESSWIRE
Feb-28-19,Horizon Pharma's (HZNP) Stock Up on Q4 Earnings &amp; Sales Beat,Zacks
Feb-28-19,Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT,Thomson Reuters StreetEvents
Mar-01-19,Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018,Zacks
Mar-01-19,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4,Zacks
Mar-04-19,BeiGene to Present at Upcoming Investor Conferences,GlobeNewswire
Mar-05-19,"Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Mar-06-19,BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics,Reuters
Mar-06-19,Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics,GlobeNewswire
Mar-07-19,Be cautious about the market now  and buy these 3 stocks on weakness,MarketWatch
Mar-22-19,3 Key Takeaways From BeiGene's CEO,Motley Fool
Apr-01-19,BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting,GlobeNewswire
Apr-03-19,"Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal",MarketWatch
Apr-09-19,"Heres What Hedge Funds Think About BeiGene, Ltd. (BGNE)",Insider Monkey
Apr-09-19,BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy,GlobeNewswire
Apr-29-19,BRIEF-Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017,Reuters
Apr-30-19,"Is BeiGene, Ltd. (NASDAQ:BGNE) Trading At A 24% Discount?",Simply Wall St.
May-09-19,BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million,Reuters
May-09-19,BRIEF-BeiGene Q1 Loss Per Share $0.22,Reuters
May-09-19,BeiGene Reports First Quarter 2019 Financial Results,GlobeNewswire
May-16-19,BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association,GlobeNewswire
May-31-19,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",Benzinga
Jun-04-19,BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors,GlobeNewswire
Jun-05-19,BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference,GlobeNewswire
Jun-11-19,"Is BeiGene, Ltd. (NASDAQ:BGNE) As Strong As Its Balance Sheet Indicates?",Simply Wall St.
Jun-12-19,BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML),GlobeNewswire
Jun-14-19,BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA),GlobeNewswire
Jun-14-19,BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA),GlobeNewswire
